Evolving strategies for prostate cancer chemoprevention trials : Can we really the risk for prostate cancer?LIEBERMAN, Ronald.World journal of urology (Print). 2003, Vol 21, Num 1, pp 3-8, issn 0724-4983, 6 p.Article

Chemoprevention of prostate cancer: Current status and future directions : Cancer chemopreventionLIEBERMAN, Ronald.Cancer metastasis reviews. 2002, Vol 21, Num 3-4, pp 297-309, issn 0167-7659, 13 p.Article

Chemoprevention of superficial bladder cancerLIEBERMAN, Ronald.Cancer treatment and research. 2001, Vol 106, pp 237-254, issn 0927-3042Article

Prostate cancer chemoprevention : Strategies for designing efficient clinical trialsLIEBERMAN, Ronald.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 224-229, issn 0090-4295Article

Preprostatectomy : A clinical model to study stromal-epithelial interactionsLOPACZYNSKI, Wlodek; HRUSZKEWYCZ, Andrew M; LIEBERMAN, Ronald et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 194-199, issn 0090-4295Article

Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent developmentLIEBERMAN, Ronald.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 83-90, issn 0090-4295Conference Paper

Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancerWEISS, Heidi L; URBAN, Donald A; GRIZZLE, William E et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 220-223, issn 0090-4295Article

Osteoporosis due to androgen deprivation therapy in men with prostate cancer. CommentaryDANIELL, Harry W; NEWLING, Don W. W; DANIELL et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 101-107, issn 0090-4295Conference Paper

The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men : Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention TrialSIMONEAU, Anne R; GERNER, Eugene W; MEYSKENS, Frank L et al.Cancer epidemiology, biomarkers & prevention. 2008, Vol 17, Num 2, pp 292-299, issn 1055-9965, 8 p.Article

Design considerations for efficient prostate cancer chemoprevention trialsLEE, J. Jack; LIEBERMAN, Ronald; SLOAN, Jeff A et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 205-212, issn 0090-4295Article

Executive summary of the national cancer institute workshop : Highlights and recommendationsLIEBERMAN, Ronald; NELSON, William G; SAKR, Wael A et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 4-27, issn 0090-4295Article

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancerARLEN, Philip M; GULLEY, James L; GROSENBACH, Douglas W et al.The Journal of urology. 2005, Vol 174, Num 2, pp 539-546, issn 0022-5347, 8 p.Article

Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancerTAKIMOTO, Chris H; GLOVER, Kira; LLORENS, Victor et al.Cancer epidemiology, biomarkers & prevention. 2003, Vol 12, Num 11, pp 1213-1221, issn 1055-9965, 9 p., 1Article

Luteinizing hormone-releasing hormone antagonists in prostate cancer. CommentarySTRICKER, Hans J; FAIR, William R; LIEBERMAN, Ronald et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 24-27, issn 0090-4295Conference Paper

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. CommentaryGLEAVE, Martin E; MIYAKE, Hideaki; CARROLL, Peter R et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 39-49, issn 0090-4295Conference Paper

Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasiaMARSHALL, James R; SAKR, Wael; JARRARD, David et al.Cancer epidemiology, biomarkers & prevention. 2006, Vol 15, Num 8, pp 1479-1484, issn 1055-9965, 6 p.Article

A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaSTEARNS, Vered; COOP, Andrew; SINGH, Baljit et al.Clinical cancer research. 2004, Vol 10, Num 22, pp 7583-7591, issn 1078-0432, 9 p.Article

Prostate cancer chemoprevention agent development: The national cancer institute, division of cancer prevention portfolio. DiscussionPARNES, Howard L; HOUSE, Margaret G; KAGAN, Jacob et al.The Journal of urology. 2004, Vol 171, Num 2, pp S68-S75, issn 0022-5347, 2Conference Paper

Computer-assisted image analysis-derived intermediate endpointsBOONE, Charles W; LIEBERMAN, Ronald; MAIRINGER, Thomas et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 129-131, issn 0090-4295Article

The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. CommentaryLUBECK, Deborah P; GROSSFELD, Gary D; CARROLL, Peter R et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 94-100, issn 0090-4295Conference Paper

Changes in serum proteomic patterns by presurgical α-tocopherol and L-selenomethionine supplementation in prostate cancerKIM, Jeri; PEIYU SUN; MCDONNELL, Timothy J et al.Cancer epidemiology, biomarkers & prevention. 2005, Vol 14, Num 7, pp 1697-1702, issn 1055-9965, 6 p.Article

Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancerKELLOFF, Gary J; LIEBERMAN, Ronald; STEELE, Vernon E et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 46-51, issn 0090-4295Article